Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 463 clinical trials
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).

dexamethasone
pomalidomide
bortezomib
cancer
refractory multiple myeloma
  • 0 views
  • 10 Jun, 2021
  • 37 locations
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.

bortezomib
human chorionic gonadotropin
refractory multiple myeloma
measurable disease
lenalidomide
  • 0 views
  • 29 May, 2021
  • 28 locations
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the antitumor activity of single agent of SAR442085

daratumumab
thalidomide
pomalidomide
bortezomib
measurable disease
  • 30 views
  • 16 Jun, 2021
  • 13 locations
A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.

refractory multiple myeloma
  • 22 views
  • 10 May, 2021
  • 17 locations
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

), dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination of bortezomib, lenalidomide

high dose chemotherapy
bortezomib
velcade
measurable disease
dexamethasone
  • 14 views
  • 10 Jun, 2021
  • 34 locations
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

multiple myeloma (SMM) Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival

smoldering myeloma
bone marrow procedure
dexamethasone
bone marrow plasma cells
lenalidomide
  • 12 views
  • 16 Jun, 2021
  • 62 locations
Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To assess the safety and tolerability (including local injection site tolerability) of isatuximab using the (investigational) isatuximab injector device To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: To estimate absolute …

dexamethasone
pomalidomide
refractory multiple myeloma
measurable disease
lenalidomide
  • 32 views
  • 11 Jun, 2021
  • 16 locations
4SCAR-CD44v6 T Cell Therapy Targeting Cancer

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of 4SCAR-CD44v6 T-cell therapy targeting multiple cancers. The study also aims to learn more about the function of the CD44v6 CAR-T cells and their persistency in the patients.

  • 0 views
  • 25 Jan, 2021
  • 4 locations
A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

This is an open-label, multicenter, Phase 1/2 study to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D), and to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

daratumumab
dexamethasone
bortezomib
refractory multiple myeloma
measurable disease
  • 0 views
  • 06 Jun, 2021
  • 45 locations
Multi-center Trial of Revlimid and Rituximab for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

The study is a two-arm, multi-center trial of Revlimid® and Rituximab, for the frontline treatment of patients with Chronic Lymphocytic Leukemia (CLL) designed and conducted by the CLL Research Consortium (CRC). The purpose of this study is to determine the response rate of the combination of Revlimid® and Rituximab in …

neutrophil count
platelet count
revlimid
lymphoid leukemia
cancer
  • 42 views
  • 07 Nov, 2020
  • 3 locations